Skip to content

Clinical Trial Registration of Xuefu Zhuyu Capsule

A randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the effectiveness and safety of Xuefu Zhuyu Capsules for angina pectoris after PCI

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045130
Enrollment
Unknown
Registered
2021-04-07
Start date
2021-04-15
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina after PCI

Interventions

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 30-75 years; 2. Patients with angina pectoris symptoms within 12 months after PCI; 3. Patients with Qi stagnation and blood stasis syndrome based on TCM differentiation; 4. The patient signs an informed consent form, has good compliance, and cooperates with follow-up visits and re-examinations.

Exclusion criteria

Exclusion criteria: 1. Diagnosed as STEMI, or diagnosed as NSTEMI who is at high risk by Grace score; 2. Patients with congenital heart disease, severe pulmonary hypertension, malignant tumors, severe COPD; 3. Valvular disease (LVEF 1.5 times the upper limit of normal value, Cr > 1.2 times the upper limit of normal value (refer to the laboratory test normal value of the research center Scope); Other clinically significant laboratory tests are abnormal and the investigator determines that it is not suitable to be included in the group; 5. People with allergies or allergies to the test drug Xuefu Zhuyu Capsules, excipients or similar ingredients; 6. Suspected or true history of alcohol or drug abuse; 7. Pregnant or breastfeeding women or those who have planned pregnancy in the near future and are unwilling to use contraceptive measures; 8. Patients who have participated in other clinical trials within 1 month before enrollment; 9. The investigator believes that it is not appropriate to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Reduction rate of nitroglycerin;

Secondary

MeasureTime frame
Angina pectoris symptom assessment;Seattle Angina Scale;Angina pectoris efficacy evaluation;Traditional Chinese Medicine symptoms;Assessment of anxiety and depression status of patients after PCI;

Countries

China

Contacts

Public ContactWang Jie

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

fltt_ning@163.com+86 10 88001116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026